Device Trial Radar · NCT07803679
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
308
Planned (sponsor's estimate)
Start
Jan 31, 2027
Primary completion
Apr 30, 2029
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- AmgenNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this trial is to demonstrate that Evolocumab plus routine lipid management is superior to routine lipid management alone in modifying plaque (non-calcified) volume as measured by Artificial Intelligence-enabled Quantitative Coronary Plaque Analysis (AI-QCPA) from Coronary Computed Tomography Angiography (CCTA).
Conditions
- Coronary Artery Disease
- Hypercholesterolemia
- Atheroma
- Atherosclerotic Plaque
Interventions
EvolocumabDrug
Evolocumab will be provided as a single-dose, prefilled AI pen for fixed dose subcutaneous (SC) injection.
Routine Lipid ManagementDrug
Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
AutoinjectorDevice
AI for SC injection of Evolocumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Non-Calcified Plaque (NCP) Volume from Baseline to Week 72Time frame: From Baseline to Week 72
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.